In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir.
Fifty-four isolates of cytomegalovirus (CMV) from 25 immunocompromised patients with CMV infections were examined in a plaque reduction assay to determine in vitro susceptibilities to both acyclovir and ganciclovir. Isolates were approximately 25-fold more sensitive to ganciclovir than to acyclovir. The mean +/- SD ID50 for all isolates to acyclovir was 63.1 +/- 30.2 microM, (median, 52.3 microM; range, 16.7-146.4 microM). The mean ID50 for all isolates to ganciclovir was 2.50 +/- 1.27 microM, (median, 2.15 microM; range, 0.65-7.11 microM). Exposure to acyclovir or ganciclovir for periods of 2-5 wk did not alter the mean susceptibility of clinical isolates. However, one CMV strain isolated from a renal transplant patient after 14 days of acyclovir therapy displayed the lowest susceptibility of all strains tested (acyclovir 146.4 microM; ganciclovir 7.11 microM) and may represent selection of a resistant virus population.
D000212:Acyclovir / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000998:Antiviral Agents / Q000494:pharmacology*; D003587:Cytomegalovirus / Q000187:drug effects*; D005347:Fibroblasts; D015774:Ganciclovir; D006801:Humans; D007108:Immune Tolerance; D010948:Viral Plaque Assay
D000998:Antiviral Agents; D015774:Ganciclovir; D000212:Acyclovir